Wednesday, September 5, 2018

Gossamer Bio Names Chief Scientific Officer

San Diego-based Gossamer Bio, the biopharmaceuticals firm which is focused on therapeutics in the autoimmune, allergy/inflammation and immuno-oncology disease areas, said today that it has named Luisa Salter-Cid, Ph.D., as its new Chief Scientific Officer. Salter-Cid spent the last 13 years at Bristol Myers Squibb, having served in such roles as Vice President and Head of Immunology, small molecule Immuno-Oncology and Genomics Discovery. Salter-Cid also served at La Jolla Pharmaceuticals, Genset Corp and Johnson & Johnson. Gossamer Bio said Salter-Cid will head up research and preclinical development efforts at the company. Gossamer Bio is venture backed by Hillhouse Capital, Abu Dhabi Investment Authority (ADIA), Invus, The Baupost Group, Polaris Partners, ARCH Venture Partners and Omega Funds. The company raised a massive $320M funding round in July.